Drug therapy plan

Formulate a drug therapy plan, taking into consideration the patient s medical history, concomitant medications, and previous use of medications. 

C. Patient-specific medical information must be evaluated and a drug therapy plan developed mutually with the patient. 

D. The pharmacist assures that the patient has all supplies, information and knowledge necessary to carry out the drug therapy plan. 

The pharmacist providing Pharmaceutical Care must assume ultimate responsibility for assuring that his/her patient has been able to obtain, and is appropriately using, any drugs and related products or equipment called for in the drug therapy plan. The pharmacist must also assure that the patient has a thorough understanding of the disease and the therapy/medications prescribed in the plan. 

The pharmacist regularly reviews subjective and objective monitoring parameters in order to determine if satisfactory progress is being made toward achieving desired outcomes as outlined in the drug therapy plan. 

Before giving a nonnarcotic analgesic to a patient, the nurse assesses the type, onset, and location of the pain. It is important to determine if this problem is different in any way from previous episodes of pain or discomfort. If the patient is receiving a nonnarcotic analgesic for an arthritic or musculoskeletal disorder or soft tissue inflammation, the nurse should examine the joints or areas involved. The appearance of the skin over the joint or affected area or any limitation of motion is documented. The nurse evaluates the patient s ability to carry out activities of daily living. This important information is used to develop a care plan, as well as to evaluate the response to drug therapy. 

When developing a teaching plan for the patient and family, tlie nurse emphasizes the importance of uninterrupted drug therapy. The nurse allows the patient and family time to ask questions. The nurse explores any problems that appear to be associated with tlie prescribed drug regimen and then reports them to tlie primary health care provider. The nurse reviews tlie purpose of tlie drug therapy with tlie patient and family, as well as the adverse reactions that may occur. 

Educating the Patient and Family The nurse evaluates the patient s ability to understand the therapeutic drug regimen, ability to care for himself or herself in the home environment, and ability to comply with the prescribed drug therapy. If any type of assistance is needed, the nurse provides a referral to the discharge planning coordinator or social worker. 

Mr. Elliott, age 42 years, had a UTI8 weeks ago. He failed to see his primary health care provider for a follow-up urine sample 2 weeks after completing his course of drug therapy. Mr. Elliot is in to see his primary health care provider because his symptoms of a UTI have recurred. The primary health care provider suspects that Mr. Elliott may not have followed instructions regarding treatment for his UTI. Analyze the situation to determine what points you would stress in a teaching plan for this patient. 

Identify a monitoring plan to assess for efficacy and toxicity of the recommended drug therapy. 

Design individualized drug therapy treatment plans for patients with (1) sinus bradycardia (2) AV nodal blockade (3) AF (4) PSVT (5) VPDs (6) VT (including torsades de pointes) and (7) VF. 

Develop specific drug therapy monitoring plans for the treatment plan implemented. Monitoring includes assessment of symptoms, ECG, adverse effects of drugs, and potential drug interactions. 

Construct a drug treatment plan based on the disease severity and location. Identify potential contraindications or financial barriers to drug therapy. Inquire if the patient has an aversion to or inability to properly use certain drug formulations that you may wish to recommend, such as topical (rectal) products. 

A therapeutic plan that includes non-drug and drug therapy. 

Develop a plan to assess the effectiveness of drug therapy during the first 12 weeks. 

Thus, it appears that the current practice by analysts to use AWP results in a value for the cost of a drug that is substantially in excess of marginal cost. If the estimated incremental cost per quality-adjusted life year (QALY) using AWP is very low or very high relative to benchmarks of acceptable ratios, or if drug therapy is dominated by another comparator, treatment of cost would not matter in the decision about whether to cover a drug under an insurance plan or include it on the formulary. But over a sizeable range of values reasonably close to the benchmark, the cost estimate used should affect the decision about acceptability of the product. So it seems appropriate to explore the conceptual framework that should be used for such analysis in more detail. 

Treatment Plan Based upon the criteria for initiating drug therapy of hypercholesterolemia, the physician... 

Whereas various childhood disorders have been reported to benefit from drug therapies, systematic data to support their use are usually minimal or lacking. An additional complication is the clinically significant pharmacokinetic (and perhaps pharmacodynamic) differences between the adult and younger age groups. Thus, the use of drugs in any treatment plan must be carefully considered and cautiously monitored to maintain the risk-benefit ratio in favor of the child or adolescent patient. 

---